Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rani Therapeutics Holdings Inc (RANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: RANI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.8
1 Year Target Price $7.8
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.97% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.53M USD | Price to earnings Ratio - | 1Y Target Price 7.8 |
Price to earnings Ratio - | 1Y Target Price 7.8 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 0.46 - 4.19 | Updated Date 07/11/2025 |
52 Weeks Range 0.46 - 4.19 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6984.3% |
Management Effectiveness
Return on Assets (TTM) -76.61% | Return on Equity (TTM) -1187.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35724341 | Price to Sales(TTM) 35.44 |
Enterprise Value 35724341 | Price to Sales(TTM) 35.44 | ||
Enterprise Value to Revenue 26.67 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 39237200 | Shares Floating 20910239 |
Shares Outstanding 39237200 | Shares Floating 20910239 | ||
Percent Insiders 27.79 | Percent Institutions 10.15 |
Upturn AI SWOT
Rani Therapeutics Holdings Inc
Company Overview
History and Background
Rani Therapeutics Holdings Inc. was founded in 2012. It is a clinical-stage biotherapeutics company focused on developing and commercializing novel, orally administered biologics, with a focus on replacing subcutaneous or intravenous injection of biologics with oral dose.
Core Business Areas
- RaniPill Platform: The RaniPill capsule is an orally administered drug delivery platform designed to deliver biologics, peptides, and antibodies.
- Partnering and Licensing: Rani partners with pharmaceutical companies to develop oral versions of their injectable biologics.
Leadership and Structure
Mir Imran serves as Chairman and CEO. The company has a board of directors and a management team responsible for research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- RaniPill GO: RaniPill GO is a platform being used to deliver various biologics currently delivered via injections. As Rani Therapeutics is still in the clinical stage, there are no current users or revenue. Competitors include companies developing alternative drug delivery methods, such as oral insulin products by Novo Nordisk.
Market Dynamics
Industry Overview
The pharmaceutical industry is continuously seeking more convenient and patient-friendly drug delivery methods, especially for biologics. Oral delivery is a major area of interest.
Positioning
Rani Therapeutics is positioned as an innovator in oral biologics delivery, aiming to replace injections with a more convenient pill-based method.
Total Addressable Market (TAM)
The total addressable market includes all injectable biologics that could potentially be delivered orally. This represents a multi-billion dollar market. Rani is positioned to capture a portion of this TAM by partnering with pharmaceutical companies.
Upturn SWOT Analysis
Strengths
- Novel Drug Delivery Technology
- Strong intellectual property portfolio
- Experienced management team
- Potential to improve patient compliance
Weaknesses
- Clinical-stage company with no approved products
- Reliance on partnerships for development and commercialization
- High risk of clinical trial failure
- Significant capital requirements for development
Opportunities
- Partnerships with major pharmaceutical companies
- Expansion of RaniPill platform to new biologics
- Increasing demand for oral biologics
- Positive clinical trial results
Threats
- Competition from other drug delivery technologies
- Regulatory hurdles
- Patent challenges
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Oramed Pharmaceuticals Inc. (ORMP)
Competitive Landscape
Rani has a unique oral delivery technology. Novo Nordisk focuses on oral insulin and has a substantial market share in diabetes. Rani's advantage lies in its platform's potential to deliver a wider range of biologics. Oramed is also developing oral insulin.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to its clinical stage.
Future Projections: Future growth depends on successful clinical trials and commercialization agreements. Analyst estimates vary significantly.
Recent Initiatives: Focus on advancing clinical trials of RaniPill GO and securing partnerships with pharmaceutical companies.
Summary
Rani Therapeutics is a high-risk, high-reward investment. Its innovative RaniPill technology offers significant potential, but the company faces challenges typical of clinical-stage biotechs, including regulatory hurdles and clinical trial risks. Successful clinical trials and strategic partnerships are key to future growth, but failure in either area would pose a major threat. The company's cash position needs to be carefully watched.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rani Therapeutics' website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.ranitherapeutics.com |
Full time employees 105 | Website https://www.ranitherapeutics.com | ||
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.